Bullboard - Stock Discussion Forum Arch Biopartners Inc V.ARCH

Alternate Symbol(s): ACHFF

Technology Scientific & Technical Instruments

Arch Biopartners Inc. is a portfolio-based biotechnology company focused on the development of technologies that have the potential to make a medical or commercial impact. The Company is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok... see more

Add To Watchlist

TSXV:ARCH - Post Discussion

Arch Biopartners Inc > RJ Analyst

View:

Post by Viking2233 on Mar 27, 2024 3:34pm

RJ Analyst

Nothing but total silence from our sole analyst at Raymond James. This analyst has not commented on number of material news releases:

1. Increased dosage study

2. FDA Approval for New Phase 2 AKI trial

3. 6 sites for Turkey

4. 3 sites for Canada

5. First dosing commenced

6. Pre-IND meeting with FDA for new re-purposed drug with new phase 2 trial to commence in the fall of 2024

7. No dilution or additional funding required at this time

8. Funally the Independent 3rd Party Perr review was published 10 days ago, which analyst has been waiting for.

There is a lot of postive catalysts here for the analyst to digest, I see a bug upgrade coming in my opinion.

143